PRLD
PRLD clinical trials: Prelude Therapeutics Inc
Every trial on ClinicalTrials.gov where Prelude Therapeutics Inc is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 13
- Trials linked
- 13
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
PRLD on the catalyst calendar · PRLD registry changes
- Primary completion Oct 31, 2028Sponsor estimatePhase 1NCT07905001A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast CancerPrelude Therapeutics Incorporated · Breast CancerRecruitingPRLDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2028Sponsor estimatePhase 1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics Incorporated · Polycythemia Vera (PV)RecruitingPRLDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 23, 2026ActualPhase 2NCT06682806A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationPrelude Therapeutics Incorporated · Advanced Solid TumorTerminatedPRLDLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 28, 2026ActualPhase 1NCT06560645A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationPrelude Therapeutics Incorporated · Advanced Solid TumorTerminatedPRLDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 12, 2025ActualPhase 1NCT05665530A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic MalignanciesPrelude Therapeutics Incorporated · Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)CompletedPRLDLeadONCCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 1, 2025ActualPhase 1NCT05639751PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 MutationPrelude Therapeutics Incorporated · Advanced Solid TumorCompletedPRLDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 26, 2024ActualPhase 1NCT05538572A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid TumorsPrelude Therapeutics Incorporated · Breast CancerCompletedPRLDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2024ActualPhase 1NCT05107856PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesPrelude Therapeutics Incorporated · Acute Myeloid LeukemiaTerminatedPRLDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 6, 2023ActualPhase 1NCT05159518A Study of PRT2527 in Participants With Advanced Solid TumorsPrelude Therapeutics Incorporated · SarcomaCompletedPRLDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 28, 2023ActualPhase 1NCT04089449A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and GliomasPrelude Therapeutics Incorporated · Advanced Solid TumorCompletedPRLDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 16, 2022ActualPhase 1NCT03886831A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic MalignanciesPrelude Therapeutics Incorporated · Relapsed/Refractory Advanced Solid TumorsCompletedPRLDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 6, 2023ActualPhase 1NCT04837677A Study of PRT1419 in Patients With Advanced Solid TumorsPrelude Therapeutics Incorporated · SarcomaCompletedPRLDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 21, 2022ActualPhase 1NCT04543305A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic MalignanciesPrelude Therapeutics Incorporated · Multiple MyelomaCompletedPRLDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner